New drug combo aims to shrink HER2 breast tumors before surgery
NCT ID NCT07246317
First seen Nov 25, 2025 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This phase 2 trial tests whether adding an experimental immunotherapy (QL1706) to standard chemotherapy and targeted drugs can better eliminate HER2-positive breast cancer before surgery. About 188 people with early or locally advanced disease will be randomly assigned to receive either the new combo or standard chemo plus targeted therapy. The main goal is to see if more patients have no cancer left at surgery (pathological complete response).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiaxing University
Jiaxing, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Nanyang Central Hospital
Nanyang, Henan, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital, Sun Yat-sen University (FAH-SYSU)
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The West China Second University Hospital of Sichuan University (WCSUH- SCU)
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 injection (an experimental immunotherapy) combined with trastuzumab, pertuzumab, and docetaxel
What this could lead to
If it works, this could offer a more effective pre-surgery treatment option for HER2-positive breast cancer, potentially improving long-term outcomes.
What could go wrong
This is an early phase 2 trial with only 188 participants, so results may not apply to everyone. Adding QL1706 could also increase side effects like immune-related reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.